Interactions of Volatile Anesthetics with Neurodegenerative-Disease-Associated Proteins

Anesthesiology Clinics of North America

Volumn 24, Issue 2, 2006, Pages 381-405

  Carnini, Anna ^a   Fazen Eckenhoff, Maryellen ^a   Eckenhoff, Roderic G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-40]; ATAXIN 1; BENZODIAZEPINE; HALOTHANE; HUNTINGTIN; HYPNOTIC AGENT; INHALATION ANESTHETIC AGENT; ISOFLURANE; PRION PROTEIN; PROPOFOL; TAU PROTEIN;

ALZHEIMER DISEASE; ANESTHESIA COMPLICATION; BINDING COMPETITION; BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG COMPETITION; ENVIRONMENTAL FACTOR; GENERAL ANESTHESIA; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; LIFE EXPECTANCY; MOLECULAR INTERACTION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; POSTOPERATIVE PAIN; PREMEDICATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SCRAPIE; SPINOCEREBELLAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANESTHETICS, INHALATION; ANIMALS; CAENORHABDITIS ELEGANS; DROSOPHILA; HUMANS; MICE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; VOLATILIZATION;

EID: 33747695707     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2006.02.002     Document Type: Review

References (112)

1. Hebert L.E., Scherr P.A., Bienias J.L., et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60 8 (2003) 1119-1122
2. Small G.W., Rabins P.V., Barry P.P., et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 278 16 (1997) 1363-1371
3. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol Clin 14 2 (1996) 317-335
4. Albers J.W., Wald J.J., Trask C.L., et al. Evaluation of blink reflex results obtained from workers previously diagnosed with solvent-induced toxic encephalopathy. J Occup Environ Med 43 8 (2001) 713-722
5. Moller J.T., Cluitmans P., Rasmussen L.S., et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. [Erratum appears in Lancet 1998;351(9117):1742]. Lancet 351 9106 (1998) 857-861
6. Nishikawa K., Nakayama M., Omote K., et al. Recovery characteristics and post-operative delirium after long-duration laparoscope-assisted surgery in elderly patients: propofol-based vs. sevoflurane-based anesthesia. Acta Anaesthesiol Scand 48 (2004) 162-168
7. Ancelin M.L., de Roquefeuil G., Ledesert B., et al. Exposure to anaesthetic agents, cognitive functioning and depressive symptomatology in the elderly. Br J Psychiatry 178 (2001) 360-366
8. Johnson T., Monk T., Rasmussen L.S., et al. Postoperative cognitive dysfunction in middle-aged patients. Anesthesiology 96 6 (2002) 1351-1357
9. Bedford P.D. Adverse cerebral effects of anesthesia on old people. Lancet ii (1955) 259-263
10. Breteler M.M., Claus J.J., van Duijn C.M., et al. Epidemiology of Alzheimer's disease. Epidemiol Rev 14 (1992) 59-82
11. Kawas C.H., and Katzman R. Epidemiology of Dementia and Alzheimer Disease. In: Terry R.D., Katzman R., Bick K.L., et al. (Eds). Alzheimer Disease (1999), Lippincott Williams & Wilkins, Philadelphia 95-116
12. Stromer T., and Serpell L.C. Structure and morphology of the Alzheimer's amyloid fibril. Microsc Res Tech 67 3-4 (2005) 210-217
13. Seabrook G.R., Smith D.W., Bowery B.J., et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacol 38 3 (1999) 349-359
14. Muller U., Cristina N., Li Z.W., et al. Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. Cell 79 5 (1994) 755-765
15. Zheng H., Jiang M., Trumbauer M.E., et al. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81 4 (1995) 525-531
16. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. [Erratum appears in Science 2002;297(5590):2209]. Science 297 5580 (2002) 353-356
17. Terry R.D., Masliah E., and Hansen L.L. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In: Terry R.D., Katzman R., Bick K.L., et al. (Eds). Alzheimer Disease (1999), Lippincott Williams and Wilkins, Philadelphia 187-206
18. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 24 4 (2001) 219-224
19. Kayed R., Head E., Thompson J.L., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 5618 (2003) 486-489
20. Klein W.L., Stine Jr. W.B., and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25 5 (2004) 569-580
21. Glabe C.G., and Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2005). Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed &dopt=Abstract&list_uids=16361390&itool=iconabstr&query_ hl=13&itool=pubmed_docsum Accessed February 27, 2006
22. Muchowski P.J., and Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6 1 (2005) 11-22
23. Auluck P.K., Meulener M.C., and Bonini N.M. Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 280 4 (2005) 2873-2878
24. Wisniewski T., and Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol 15 1 (2005) 72-77
25. Bayer A.J., Bullock R., Jones R.W., et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 1 (2005) 94-101
26. Schenk D., Hagen M., and Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16 5 (2004) 599-606
27. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 6740 (1999) 173-177
28. Weiner H.L., Lemere C.A., Maron R., et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48 4 (2000) 567-579
29. Janus C., Pearson J., McLaurin J., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 6815 (2000) 979-982
30. Jensen M.T., Mottin M.D., Cracchiolo J.R., et al. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 130 3 (2005) 667-684
31. Lemere C.A., Beierschmitt A., Iglesias M., et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165 1 (2004) 283-297
32. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 8 (2000) 916-919
33. DeMattos R.B., Bales K.R., Cummins D.J., et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 15 (2001) 8850-8855
34. Oddo S., Billings L., Kesslak J.P., et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 3 (2004) 321-332
35. McLaurin J., Cecal R., Kierstead M.E., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8 11 (2002) 1263-1269
36. Oddo S., Caccamo A., Smith I., et al. A dynamic relationship between intracellular and extracellular pools of aβ. Am J Pathol 168 1 (2006) 184-194
37. Morgan D., Diamond D.M., Gottschall P.E., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. [Erratum appears in Nature 2001;412(6847):660]. Nature 408 6815 (2000) 982-985
38. Kotilinek L.A., Bacskai B., Westerman M., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22 15 (2002) 6331-6335
39. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 1 1 (2002) 3
40. Orgogozo J.M., Gilman S., Dartigues J.F., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 1 (2003) 46-54
41. Michaelis M.L. Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther 304 3 (2003) 897-904
42. De Felice F.G., Vieira M.N., Saraiva L.M., et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J 18 12 (2004) 1366-1372
43. Lashuel H.A., Hartley D.M., Balakhaneh D., et al. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem 277 45 (2002) 42881-42890
44. LaFerla F.M., and Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11 4 (2005) 170-176
45. Binder L.I., Guillozet-Bongaarts A.L., Garcia-Sierra F., et al. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 1739 2-3 (2005) 216-223
46. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 24 (2001) 1121-1159
47. Forman M.S., Trojanowski J.Q., and Lee V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10 10 (2004) 1055-1063
48. Kotzbauer P.T., Trojanowsk J.Q., and Lee V.M. Lewy body pathology in Alzheimer's disease. J Mol Neurosci 17 2 (2001) 225-232
49. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2 7 (2001) 492-501
50. Norris E.H., Giasson B.I., and Lee V.M. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 60 (2004) 17-54
51. Bennett M.C. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 105 3 (2005) 311-331
52. Masliah E., Rockenstein E., Veinbergs I., et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98 21 (2001) 12245-12250
53. Gotz J., Chen F., van Dorpe J., et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293 5534 (2001) 1491-1495
54. Giasson B.I., Forman M.S., Higuchi M., et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 5619 (2003) 636-640
55. Kotzbauer P.T., Giasson B.I., Kravitz A.V., et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 187 2 (2004) 279-288
56. Frasier M., and Wolozin B. Following the leader: fibrillization of alpha-synuclein and tau. Exp Neurol 187 2 (2004) 235-239
57. Zoghbi H.Y., and Orr H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23 (2000) 217-247
58. Weissmann C. The state of the prion. Nat Rev Microbiol 2 11 (2004) 861-871
59. DeArmond S.J., and Prusiner S.B. Perspectives on prion biology, prion disease pathogenesis, and pharmacologic approaches to treatment. Clin Lab Med 23 1 (2003) 1-41
60. Prusiner S.B., Scott M.R., DeArmond S.J., et al. Prion protein biology. Cell 93 3 (1998) 337-348
61. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81 11 (2003) 678-699
62. Dobson C.M. Protein folding and misfolding. Nature 426 6968 (2003) 884-890
63. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6 11 (2004) 1054-1061
64. Bucciantini M., Calloni G., Chiti F., et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 279 30 (2004) 31374-31382
65. Petkova A.T., Ishii Y., Balbach J.J., et al. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99 26 (2002) 16742-16747
66. Kanno T., Yamaguchi K., Naiki H., et al. Association of thin filaments into thick filaments revealing the structural hierarchy of amyloid fibrils. J Struct Biol 149 2 (2005) 213-218
67. Oddo S., Caccamo A., Tran L., et al. Temporal profile of Abeta oligomerization in an in vivo model of Alzheimer's disease: a link between Abeta and tau pathology. J Biol Chem 281 3 (2006) 1599-1604
68. Eckenhoff R.G., and Johansson J.S. Molecular interactions between inhaled anesthetics and proteins. Pharmacol Rev 49 4 (1997) 343-367
69. Eckenhoff R.G., Petersen C.E., Ha C.E., et al. Inhaled anesthetic binding sites in human serum albumin. J Biol Chem 275 39 (2000) 30439-30444
70. Kutchai H., Geddis L.M., Jones L.R., et al. Differential effects of general anesthetics on the quaternary structure of the Ca-ATPases of cardiac and skeletal sarcoplasmic reticulum. Biochemistry 37 8 (1998) 2410-2421
71. Eckenhoff R.G., Pidikiti R., and Reddy K.S. Anesthetic stabilization of protein intermediates: myoglobin and halothane. Biochemistry 40 36 (2001) 10819-10824
72. Hubbard S.J., and Argos P. Cavities and packing at protein interfaces. Protein Sci 3 12 (1994) 2194-2206
73. Chatani E., and Goto Y. Structural stability of amyloid fibrils of beta(2)-microglobulin in comparison with its native fold. Biochim Biophys Acta 1753 1 (2005) 64-75
74. Eckenhoff R.G., Johansson J.S., Wei H., et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 101 3 (2004) 703-709
75. Link C.D. Invertebrate models of Alzheimer's disease. Genes Brain Behav 4 3 (2005) 147-156
76. Bilen J., and Bonini N.M. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 39 (2005) 153-171
77. Warrick J.M., Chan H.Y., Chai Y., et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23 4 (1999) 425-428
78. Link C.D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92 20 (1995) 9368-9372
79. Link C.D., Johnson C.J., Fonte V., et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 22 2 (2001) 217-226
80. Link C.D., Taft A., Kapulkin V., et al. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol Aging 24 3 (2003) 397-413
81. Iijima K., Liu H.P., Chiang A.S., et al. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci USA 101 17 (2004) 6623-6628
82. Greeve I., Kretzschmar D., Tschape J.A., et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 24 16 (2004) 3899-3906
83. Auluck P.K., Chan H.Y., Trojanowski J.Q., et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 5556 (2002) 865-868
84. Nishimura I., Yang Y., and Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116 5 (2004) 671-682
85. Jackson G.R., Wiedau-Pazos M., Sang T.K., et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34 4 (2002) 509-519
86. Stephan A., and Phillips A.G. A case for a non-transgenic animal model of Alzheimer's disease. Genes Brain Behav 4 3 (2005) 157-172
87. Kobayashi D.T., and Chen K.S. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav 4 3 (2005) 173-196
88. Games D., Adams D., Alessandrini R., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 6514 (1995) 523-527
89. Chen G., Chen K.S., Knox J., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408 6815 (2000) 975-979
90. Hsiao K., Chapman P., Nilsen S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 5284 (1996) 99-102
91. Westerman M.A., Cooper-Blacketer D., Mariash A., et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22 5 (2002) 1858-1867
92. Van Dam D., D'Hooge R., Staufenbiel M., et al. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17 2 (2003) 388-396
93. Sturchler-Pierrat C., Abramowski D., Duke M., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94 24 (1997) 13287-13292
94. Winkler D.T., Bondolfi L., Herzig M.C., et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21 5 (2001) 1619-1627
95. Chishti M.A., Yang D.S., Janus C., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276 24 (2001) 21562-21570
96. Holcomb L., Gordon M.N., McGowan E., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4 1 (1998) 97-100
97. Arendash G.W., King D.L., Gordon M.N., et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891 1-2 (2001) 42-53
98. McGowan E., Sanders S., Iwatsubo T., et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6 4 (1999) 231-244
99. Kurt M.A., Davies D.C., Kidd M., et al. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp Neurol 171 1 (2001) 59-71
100. Howlett D.R., Richardson J.C., Austin A., et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 1017 1-2 (2004) 130-136
101. Ohno M., Sametsky E.A., Younkin L.H., et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41 1 (2004) 27-33
102. Lewis J., McGowan E., Rockwood J., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. [Erratum appears in Nat Genet 2000;26(1):127]. Nat Genet 25 4 (2000) 401-405
103. Oddo S., Caccamo A., Shepherd J.D., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 3 (2003) 409-421
104. Billings L.M., Oddo S., Green K.N., et al. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 5 (2005) 675-688
105. Culley D.J., Baxter M.G., Crosby C.A., et al. Impaired acquisition of spatial memory 2 weeks after isoflurane and isoflurane-nitrous oxide anesthesia in aged rats. Anesth Analg 99 5 (2004) 1393-1397
106. Jevtovic-Todorovic V., Hartman R.E., Izumi Y., et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 23 3 (2003) 876-882
107. Jevtovic-Todorovic V., and Carter L.B. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. Neurobiol Aging 26 6 (2005) 947-956
108. Bohnen N., Warner M.A., Kokmen E., et al. Alzheimer's disease and cumulative exposure to anesthesia: a case-control study. J Am Geriatr Soc 42 2 (1994) 198-201
109. Muravchick S., and Smith D.S. Parkinsonian symptoms during emergence from general anesthesia. Anesthesiology 82 1 (1995) 305-307
110. Bohnen N., Warner M.A., Kokmen E., et al. Early and midlife exposure to anesthesia and age of onset of Alzheimer's disease. Intern J Neurosci 77 3-4 (1994) 181-185
111. Gasparini M., Vanacore N., Schiaffini C., et al. A case-control study on Alzheimer's disease and exposure to anesthesia. Neurol Sci 23 1 (2002) 11-14
112. Lee T.A., Wolozin B., Weiss K.B., et al. Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheimers Dis 7 4 (2005) 319-324